Systemic sclerosis & Raynaud's
Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies
Authors' conclusion
These analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA, and ATA had a higher rate of progression than the overall trial population
Study context
- Population
- Patients with SSc-ILD in the SENSCIS trial (nintedanib vs placebo) with baseline serological evaluation
- Comparison
- Rate of forced vital capacity (FVC) decline in serological subsets (anticentromere antibody (ACA)+, ARA+, ACA/ARA/ATA-negative) vs overall SENSCIS population, by nintedanib or placebo
- ACA positiven = 32
- ARA positiven = 98
- ACA, ARA, ATA negativen = 127
- Primary endpoint
- Rate of decline in FVC
- Follow-up
- 52 weeks
Methodological detailsserological subsets
- Serological subsets
Primary result
As reported in the abstract
Adjusted rate (SE) of FVC decline, placebo
ACA positive
−31.2
adjusted rate · SE 41.5 · mL/year
ARA positive
−64.7
adjusted rate · SE 35.1 · mL/year
ACA, ARA, ATA negative
−115.6
adjusted rate · SE 35.4 · mL/yr
Overall SENSCIS population
−93.3
adjusted rate · SE 13.5 · mL/yr
Further findings
Adjusted rate, mL/yr
| Outcome | ACA, ARA, ATA negative | Overall SENSCIS population |
|---|---|---|
| Adjusted rate (SE) of FVC decline, nintedanib · 52 weeks | −91.8 (SE 34.3) | −52.4 (SE 13.8) |
Adjusted rate (SE) of FVC decline, nintedanib · 52 weeks
- ACA/ARA/ATA negative: numerically greater decline than overall population
Original publication
Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies. J Rheumatol. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →